Avicanna Inc. Stock price

Equities

AVCN

CA05368K1003

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:59:59 2024-03-27 pm EDT 5-day change 1st Jan Change
0.51 CAD -3.77% Intraday chart for Avicanna Inc. -5.56% +45.71%
Sales 2021 3.27M 2.4M Sales 2022 4.05M 2.98M Capitalization 30.73M 22.61M
Net income 2021 -16M -11.77M Net income 2022 -14M -10.3M EV / Sales 2021 11.4 x
Net Debt 2021 1.63M 1.2M Net Debt 2022 2.02M 1.48M EV / Sales 2022 8.09 x
P/E ratio 2021
-1.92 x
P/E ratio 2022
-1.65 x
Employees 80
Yield 2021 *
-
Yield 2022
-
Free-Float 68.33%
More Fundamentals * Assessed data
Dynamic Chart
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation CI
ThreeD Capital Inc. Announces New YouTube Channel MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6% MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) MT
Avicanna Brief: Says Obtained Its First Indication-Specific Drug Registration with Trunerox MT
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox CI
Avicanna Signs Supply, Licensing Pact With Multinational Pharmaceutical Firm MT
Avicanna Inc. Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company CI
Avicanna Brief: Also Involves Right of first refusal agreement for the Avicanna's SEDDs capsules in the European region MT
Avicanna Brief: Involves Exclusive supply agreement for two of Avicanna's proprietary topical products in the European region MT
More news
1 day-3.77%
1 week-5.56%
Current month+10.87%
1 month+15.91%
3 months+37.84%
6 months+9.68%
Current year+45.71%
More quotes
1 week
0.50
Extreme 0.5
0.55
1 month
0.43
Extreme 0.43
0.60
Current year
0.30
Extreme 0.3
0.60
1 year
0.23
Extreme 0.23
0.60
3 years
0.16
Extreme 0.16
1.17
5 years
0.16
Extreme 0.16
7.40
10 years
0.16
Extreme 0.16
7.40
More quotes
Managers TitleAgeSince
Founder 37 15-04-30
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 57 Nov. 12
Founder 37 15-04-30
Director/Board Member - 21-06-23
More insiders
Date Price Change Volume
24-03-27 0.51 -3.77% 109,000
24-03-26 0.53 +3.92% 70,550
24-03-25 0.51 0.00% 18,504
24-03-22 0.51 +2.00% 38,702
24-03-21 0.5 -7.41% 24,869

Delayed Quote Toronto S.E., March 27, 2024 at 03:59 pm EDT

More quotes
Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients’ needs and enhances the patient's journey.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Avicanna Inc. - Toronto S.E.